Xencor, Inc
A biopharmaceutical company that engineers antibodies and other proteins to treat cancer and autoimmune diseases. Its XmAb platform makes precise "plug-and-play" tweaks to the stem of an antibody, and those engineered designs show up in approved drugs like Ultomiris and sotrovimab, as well as in therapies developed with partners such as Novartis and Amgen. Founded in 1997 by scientist Bassil Dahiyat in California, the company also runs its own pipeline of drug candidates.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 13GPassive | 5.13% | 3.81M | Jul 31, 2026 |
| EcoR1 Capital, LLC | 13G/APassive | 2.9% | 2.18M | May 15, 2026 |
| Oleg Nodelman | 13G/APassive | 2.9% | 2.18M | May 15, 2026 |
| EcoR1 Capital Fund Qualified, L.P. | 13G/APassive | 2.8% | 2.04M | May 15, 2026 |
| RA Capital Management, L.P. | 13GPassive | 6.5% | 4.74M | Mar 30, 2026 |
| Peter Kolchinsky | 13GPassive | 6.5% | 4.74M | Mar 30, 2026 |
| Rajeev Shah | 13GPassive | 6.5% | 4.74M | Mar 30, 2026 |
| RA Capital Healthcare Fund, L.P. | 13GPassive | 6.5% | 4.74M | Mar 30, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| BVF PARTNERS L P/IL | 13G/APassive | 9.99% | 7.13M | Feb 17, 2026 |